TSS
PTHS

Two Sigma Securities’s Pelthos Therapeutics PTHS Stock Holding History

Two Sigma Securities’s Portfolio PTHS Stock Details PTHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,435
Closed -$9.2K – 2333
2024
Q4 		$9.2K Sell
1,435
-1,171
-45% -$7.61K ﹤0.01% 1442
2024
Q3 		$18.5K Buy
+2,606
New +$25.4K ﹤0.01% 2510

Other funds holding PTHS

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TCM
Tradewinds Capital Management Bellingham, Washington $504M AUM 40.92% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Securities's PTHS Position: Q1 2025 in Review

Two Sigma Securities sold out of Pelthos Therapeutics (PTHS) in Q1 2025, closing a stake of 1,435 shares — an estimated $9.2K sold.

Two Sigma Securities first reported a position in PTHS in Q3 2024 and held it in 2 quarters. The position peaked at $18.5K in Q3 2024. 9 funds tracked by Wall St. Rank hold PTHS as of Q1 2025.

  • Two Sigma Securities reported no remaining Pelthos Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Securities sold 1,435 Pelthos Therapeutics shares in Q1 2025, an estimated $9.2K.
  • Two Sigma Securities first reported a position in Pelthos Therapeutics in Q3 2024 and held it in 2 quarters.
  • Two Sigma Securities's Pelthos Therapeutics position peaked at $18.5K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held Pelthos Therapeutics as of Q1 2025.

Based on Two Sigma Securities's 13F filing for Q1 2025, filed 15 May 2025.